Drugs / LILRB4 STAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05548088 | May 2023 → Aug 2024 | myeloid leukemia | Peking University People's Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05739409 | Feb → May 2023 | acute myeloid leukemia, chronic myelomonocytic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LILRB4 STAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05548088 ↗ |
| Modality | Cell therapy | “followed by infusion of LILRB4 STAR-T cells.” NCT05548088 ↗ |
| Route | Intravenous | “STAR-T cells will be intravenously infused” NCT05548088 ↗ |